BreezeBio
South San Francisco · Founded 2016
About BreezeBio
GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. The company's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases.
Company Facts
- Founded: 2016
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $127.7M
- Funding stage: Early Stage Venture
- Last round: Series B (Feb 2026)
- Website: https://breezebio.com/
- Phone: 01094940632
Industries & Categories
Biotechnology, Genetics, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/breezebio-62112 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.